Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides

Todd A. Aguilera, Emilia S. Olson, Margaret M. Timmers, Tao Jiang, Roger Y. Tsien

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Cell penetrating peptides (CPPs) have been developed as vehicles for payload delivery into cells in culture and in animals. However several biologic features limit their usefulness in living animals. Activatable cell penetrating peptides (ACPPs) are polycationic CPPs whose adsorption and cellular uptake are minimized by a covalently attached polyanionic inhibitory domain. Cleavage of the linker connecting the polyanionic and polycationic domains by specific proteases (tumor associated matrix metalloproteases discussed herein) dissociates the polyanion and enables the cleaved ACPP to enter cells. In contrast to their CPP counterpart, ACPPs are relatively nonadherent and distributed uniformly to normal tissues. While nonaarginine (r9) CPP administered intravenously into mice initially bind to the local vasculature and redistribute to the liver, where >90% of the injected dose accumulates 30 min after injection. Regardless of the presence of the polyanionic inhibitory domain, confocal imaging of live tissues reveals that the majority of the ACPP and CPP remain in punctate organelles, presumably endosomes. Therefore further improvements in the efficiency of delivery to the cytosol and nucleus are necessary. In addition to improved target specificity, a major advantage of ACPPs over CPPs for potential clinical applications is reduced toxicity. Systemically administered r9 CPP causes acute toxicity in mice at a dose 4-fold lower than the MMP cleavable ACPP, a complication not observed with an uncleavable ACPP presumably because the polycationic charge remains masked systemically. These data suggest that ACPPs have greater potential than CPPs for systemic delivery of imaging and therapeutic agents.

Original languageEnglish (US)
Pages (from-to)371-381
Number of pages11
JournalIntegrative Biology
Volume1
Issue number5-6
DOIs
StatePublished - Dec 1 2009

Fingerprint

Cell-Penetrating Peptides
Toxicity
Animals
Tissue
Imaging techniques

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Medicine(all)

Cite this

Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. / Aguilera, Todd A.; Olson, Emilia S.; Timmers, Margaret M.; Jiang, Tao; Tsien, Roger Y.

In: Integrative Biology, Vol. 1, No. 5-6, 01.12.2009, p. 371-381.

Research output: Contribution to journalArticle

Aguilera, Todd A. ; Olson, Emilia S. ; Timmers, Margaret M. ; Jiang, Tao ; Tsien, Roger Y. / Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. In: Integrative Biology. 2009 ; Vol. 1, No. 5-6. pp. 371-381.
@article{4a03ab1b60bc4382a210803988172d39,
title = "Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides",
abstract = "Cell penetrating peptides (CPPs) have been developed as vehicles for payload delivery into cells in culture and in animals. However several biologic features limit their usefulness in living animals. Activatable cell penetrating peptides (ACPPs) are polycationic CPPs whose adsorption and cellular uptake are minimized by a covalently attached polyanionic inhibitory domain. Cleavage of the linker connecting the polyanionic and polycationic domains by specific proteases (tumor associated matrix metalloproteases discussed herein) dissociates the polyanion and enables the cleaved ACPP to enter cells. In contrast to their CPP counterpart, ACPPs are relatively nonadherent and distributed uniformly to normal tissues. While nonaarginine (r9) CPP administered intravenously into mice initially bind to the local vasculature and redistribute to the liver, where >90{\%} of the injected dose accumulates 30 min after injection. Regardless of the presence of the polyanionic inhibitory domain, confocal imaging of live tissues reveals that the majority of the ACPP and CPP remain in punctate organelles, presumably endosomes. Therefore further improvements in the efficiency of delivery to the cytosol and nucleus are necessary. In addition to improved target specificity, a major advantage of ACPPs over CPPs for potential clinical applications is reduced toxicity. Systemically administered r9 CPP causes acute toxicity in mice at a dose 4-fold lower than the MMP cleavable ACPP, a complication not observed with an uncleavable ACPP presumably because the polycationic charge remains masked systemically. These data suggest that ACPPs have greater potential than CPPs for systemic delivery of imaging and therapeutic agents.",
author = "Aguilera, {Todd A.} and Olson, {Emilia S.} and Timmers, {Margaret M.} and Tao Jiang and Tsien, {Roger Y.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1039/b904878b",
language = "English (US)",
volume = "1",
pages = "371--381",
journal = "Integrative Biology (United Kingdom)",
issn = "1757-9694",
publisher = "Royal Society of Chemistry",
number = "5-6",

}

TY - JOUR

T1 - Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides

AU - Aguilera, Todd A.

AU - Olson, Emilia S.

AU - Timmers, Margaret M.

AU - Jiang, Tao

AU - Tsien, Roger Y.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Cell penetrating peptides (CPPs) have been developed as vehicles for payload delivery into cells in culture and in animals. However several biologic features limit their usefulness in living animals. Activatable cell penetrating peptides (ACPPs) are polycationic CPPs whose adsorption and cellular uptake are minimized by a covalently attached polyanionic inhibitory domain. Cleavage of the linker connecting the polyanionic and polycationic domains by specific proteases (tumor associated matrix metalloproteases discussed herein) dissociates the polyanion and enables the cleaved ACPP to enter cells. In contrast to their CPP counterpart, ACPPs are relatively nonadherent and distributed uniformly to normal tissues. While nonaarginine (r9) CPP administered intravenously into mice initially bind to the local vasculature and redistribute to the liver, where >90% of the injected dose accumulates 30 min after injection. Regardless of the presence of the polyanionic inhibitory domain, confocal imaging of live tissues reveals that the majority of the ACPP and CPP remain in punctate organelles, presumably endosomes. Therefore further improvements in the efficiency of delivery to the cytosol and nucleus are necessary. In addition to improved target specificity, a major advantage of ACPPs over CPPs for potential clinical applications is reduced toxicity. Systemically administered r9 CPP causes acute toxicity in mice at a dose 4-fold lower than the MMP cleavable ACPP, a complication not observed with an uncleavable ACPP presumably because the polycationic charge remains masked systemically. These data suggest that ACPPs have greater potential than CPPs for systemic delivery of imaging and therapeutic agents.

AB - Cell penetrating peptides (CPPs) have been developed as vehicles for payload delivery into cells in culture and in animals. However several biologic features limit their usefulness in living animals. Activatable cell penetrating peptides (ACPPs) are polycationic CPPs whose adsorption and cellular uptake are minimized by a covalently attached polyanionic inhibitory domain. Cleavage of the linker connecting the polyanionic and polycationic domains by specific proteases (tumor associated matrix metalloproteases discussed herein) dissociates the polyanion and enables the cleaved ACPP to enter cells. In contrast to their CPP counterpart, ACPPs are relatively nonadherent and distributed uniformly to normal tissues. While nonaarginine (r9) CPP administered intravenously into mice initially bind to the local vasculature and redistribute to the liver, where >90% of the injected dose accumulates 30 min after injection. Regardless of the presence of the polyanionic inhibitory domain, confocal imaging of live tissues reveals that the majority of the ACPP and CPP remain in punctate organelles, presumably endosomes. Therefore further improvements in the efficiency of delivery to the cytosol and nucleus are necessary. In addition to improved target specificity, a major advantage of ACPPs over CPPs for potential clinical applications is reduced toxicity. Systemically administered r9 CPP causes acute toxicity in mice at a dose 4-fold lower than the MMP cleavable ACPP, a complication not observed with an uncleavable ACPP presumably because the polycationic charge remains masked systemically. These data suggest that ACPPs have greater potential than CPPs for systemic delivery of imaging and therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=77749335904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749335904&partnerID=8YFLogxK

U2 - 10.1039/b904878b

DO - 10.1039/b904878b

M3 - Article

VL - 1

SP - 371

EP - 381

JO - Integrative Biology (United Kingdom)

JF - Integrative Biology (United Kingdom)

SN - 1757-9694

IS - 5-6

ER -